Open AccessIn vitro antibacterial activity of ME1207, a new oral cephalosporin
Author(s) -
Shunichi Miyazaki,
Yoshitugu Miyazaki,
Akiyoshi Tsuji,
Motohiro Nishida,
Shinichi Goto
Publication year - 1991
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.35.8.1691
Subject(s) - microbiology and biotechnology , morganella morganii , enterococcus faecalis , citrobacter freundii , cefixime , cefpodoxime , cephalosporin , enterococcus faecium , pseudomonas aeruginosa , biology , ceftizoxime , enterococcus , cefaclor , providencia , haemophilus influenzae , enterobacter , staphylococcus aureus , antibiotics , bacteria , klebsiella pneumoniae , escherichia coli , biochemistry , genetics , gene
ME1207 is the prodrug of ME1206. Its in vitro antibacterial activity was compared with that of cefteram, cefpodoxime, cefixime, and cefaclor against various clinical isolates. ME1206 was more active than the other cephems tested against staphylococci, streptococci, Morganella morganii, Pseudomonas cepacia, and Flavobacterium meningosepticum and had the most potent activity against Haemophilus influenzae and Neiserria gonorrhoeae. The drug also showed a wide spectrum of activity against other gram-positive and gram-negative bacteria, except methicillin-resistant Staphylococcus aureus, Enterococcus faecalis, Citrobacter freundii, Pseudomonas aeruginosa, Xanthomonas maltophilia, and Alcaligenes xylosoxydans.